Indirect comparison of the effects of anti-TNF biological agents in patients with Ankylosing Spondylitis by means of a Mixed Treatment Comparison performed on efficacy data from published randomised, controlled trials

References

• Sieper J. Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Res Ther 2009;11:208
   PubMed Web of Science ®Google Scholar
• Wittoek R, Mielants H. Clinical assessment in the spondyloarthropathies. Adv Exp Med Biol 2009;649:1–16
   Google Scholar
• Sengupta R, Stone MA. The assessment of ankylosing spondylitis in clinical practice. Nat Clin Pract Rheumatol 2007;3:496–503
   PubMedGoogle Scholar
• Brandt J, Sieper J, Braun J. Infliximab in the treatment of active and severe ankylosing spondylitis. Clin Exp Rheumatol 2002;20:S106–10
   Google Scholar
• Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180–210
   PubMedGoogle Scholar
• McCormack PL, Wellington K. Etanercept: in ankylosing spondylitis. BioDrugs 2004;18:199–205; discussion 206
   PubMed Web of Science ®Google Scholar
• Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002;41:1280–5
   PubMed Web of Science ®Google Scholar
• Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316–20
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Enbrel 25mg powder and solvent for solution for injection: summary of product characteristics (online). http:www.emea.eu. Accessed September 5, 2006
   Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63
   PubMed Web of Science ®Google Scholar
• Bennett AN, Peterson P, Zain A, et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005;44:1026–31
   PubMed Web of Science ®Google Scholar
• Pavelka K, Forejtová S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009;27:958–63
   Google Scholar
• Migliore A, Bizzi E, Laganà B, et al. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol 2009;22:415–26
   PubMed Web of Science ®Google Scholar
• Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956–64
   PubMed Web of Science ®Google Scholar
• Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1–19
   PubMed Web of Science ®Google Scholar
• Ades AE, Welton N, Lu G. Introduction to mixed treatment comparisons. Bristol, United Kingdom: University of Bristol, 2007
   Google Scholar
• Caldwell D, Ades A, Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897–900
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–24
   PubMed Web of Science ®Google Scholar
• van Tubergen A, van der Heijde D, Anderson J, et al. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis 2003;62:215–21
   PubMedGoogle Scholar
• van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136–46
   PubMed Web of Science ®Google Scholar
• Davis JC, Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230–6
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dijkmans B, Geusens P, et al. Ankylosing Spondylitis Study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582–91
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Lu G, et al. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006;166:1269–75
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58
   PubMed Web of Science ®Google Scholar
• Welton N, Caldwell D, Adamopoulous, E, et al. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol 2009;169:1158–65
   PubMed Web of Science ®Google Scholar
• Jansen JP, Bergman GJ, Huels J, et al. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin 2009;25:1861–8
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007;46:1450–3
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Braun J. Anti-TNF-alpha therapy with infliximab in spondyloarthritides. Expert Rev Clin Immunol 2010;6:9–19
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weissman BN, et al. ATLAS study group assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324–3
   PubMed Web of Science ®Google Scholar